Targets › HCVNS5A
1 program from 1 company in 1 trial: 1 Phase 1; Infectious disease; next expected readout Mar 2028.
Open in Phaseline: the race on HCVNS5A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Pibrentasvir Nonstructural protein 5A inhibitor | HCVNS3, HCVNS5A | Phase 1 | Hepatitis C | Mar 2028 |
Hepatitis C (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.